NUNZIA PHARMACEUTICAL Co (NUNZ) financial statements (2022 and earlier)

Company profile

Business Address 1627 WEST 14TH STREET
LONG BEACH, CA 90813
State of Incorp. UT
Fiscal Year End December 31
SIC 8741 - Management Services (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments0217 
Cash and cash equivalents0217 
Prepaid expense43  
Total current assets:4417 
Noncurrent Assets
Other undisclosed noncurrent assets55  
Total noncurrent assets:55  
TOTAL ASSETS:9917 
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:  2426
Other undisclosed accounts payable and accrued liabilities  2426
Due to related parties86374411
Other undisclosed current liabilities1126  
Total current liabilities:98636936
Noncurrent Liabilities
Other undisclosed noncurrent liabilities232323 
Total noncurrent liabilities:232323 
Total liabilities:121869236
Stockholders' equity
Stockholders' equity attributable to parent, including:(111)(77)(75)(36)
Additional paid in capital101,00392,00692,00629
Accumulated deficit(101,407)(101,373)(101,366)(9,350)
Other undisclosed stockholders' equity attributable to parent2939,2909,2859,285
Total stockholders' equity:(111)(77)(75)(36)
TOTAL LIABILITIES AND EQUITY:9917 

Income statement (P&L) ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
Operating expenses(35)(7)(16)(1)
Operating loss:(35)(7)(16)(1)
Other undisclosed loss from continuing operations before equity method investments, income taxes   (9,000)
Net loss available to common stockholders, diluted:(35)(7)(16)(9,001)

Comprehensive Income ($ in thousands)

9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
Net loss:(35)(7)(16)(9,001)
Comprehensive loss, net of tax, attributable to parent:(35)(7)(16)(9,001)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: